Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model

Head and Neck

Volumn 25, Issue 7, 2003, Pages 554-560

  Chen, Fang An ^a   Kuriakose, M Abraham ^a   Zhou, Ming Xing ^b   DeLacure, Mark D ^a   Dunn, Richard L ^b  

^a Division of Head and Neck Surgery   (United States)

^b QLT Inc   (United States)

Author keywords

Chemotherapy; Cisplatin; Drug delivery; Head and neck cancer; Maximum tolerated dose

Indexed keywords

CISPLATIN; POLYMER;

ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIODEGRADABILITY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIODEGRADATION, ENVIRONMENTAL; CARCINOMA, SQUAMOUS CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, SCID; MODELS, ANIMAL; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ATOMIC;

EID: 0037633151     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10241     Document Type: Article

References (20)

1. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504.
2. Levin L, Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 1987;14:12-19.
3. Riley C, Sternson LA. Cisplatin. Anal Profiles Drug Substances 1985;14:77-104.
4. Hanada K, Nishijima K, Ogata H, Atagi S, Kawahara M. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 2001; 31:179-184.
5. Tandy JR, Tandy RD, Farris P, Truelson JM. In vivo interaction of cis-platinum and fosfomycin on squamous cell carcinoma. Laryngoscope 2000;110:1222-1224.
6. Burris HA 3rd, Vogel CL, Castro D, et al. Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 1998;118:496-503.
7. Monga SP, Wadleigh R, Sharma A, et al. Intratumoral therapy of cisplatin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol 2000;23:386-392.
8. Mok TS, Kanekal S, Lin XR, et al. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 2001;91: 2369-2377.
9. Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for the treatment of metastatic canine osteosarcoma. Eur J Exp Musculoskel Res 1995;4: 105-110.
10. Lana SE, Dernell WS, LaRue SM, et al. Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet Radiol Ultrasound 1997;38: 474-478.
11. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999;35: 994-1002.
12. Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol 2000;46:10-18.
13. Li H, Wang C, Wen Y, Wu H. Treatment of squamous cell carcinoma of the tongue using arterial embolism with cisplatin-loaded albumin microspheres: a microstructural and ultrastructural investigation. Chin J Dent Res 1999; 2:61-66.
14. Nishita T. Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor. Osaka City Med J 1998;44:73-83.
15. Polson AM, Southard GL, Dunn RL, Polson AP. Healing patterns associated with an Atrisorb barrier in guided tissue regeneration. Compendium 1993;14:1162, 1164, 1166 passim; quiz 1172.
16. Polson AM, Southard GL, Dunn RL, et al. Periodontal healing after guided tissue regeneration with Atrisorb barriers in beagle dogs. International J Periodont Restor Dent 1995;15:574-589.
17. Polson AM, Southard GL, Dunn RL, Polson AP, Billen JR, Laster LL. Initial study of guided tissue regeneration in Class II furcation defects after use of a biodegradable barrier. Int J Periodont Restor Dent 1995;15:42-55.
18. Coonts BA, Whitman SL, O'Donnell M, et al. Biodegradation and biocompatibility of a guided tissue regeneration barrier membrane formed from a liquid polymer material. J Biomed Mater Res 1998;42:303-311.
19. Andriano KP, Chandrashekar B, McEnery K, et al. Preliminary in vivo studies on the osteogenic potential of bone morphogenetic proteins delivered from an absorbable puttylike polymer matrix. J Biomed Mater Res 2000; 53:36-43.
20. Ravivarapu HB, Moyer KL, Dunn RL. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J Pharm Sci 2000; 89:732-741.